42 research outputs found
BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations
Genome-wide association studies have successfully identified 20 colorectal cancer susceptibility loci. Amongst these, four of the signals are defined by tagging single nucleotide polymorphisms (SNPs) on regions 14q22.2 (rs4444235 and rs1957636) and 20p12.3 (rs961253 and rs4813802). These markers are located close to two of the genes involved in bone morphogenetic protein (BMP) signaling (BMP4 and BMP2, respectively). By investigating these four SNPs in an initial cohort of Spanish origin, we found substantial evidence that minor allele frequencies (MAFs) may be different in northern and southern European populations. Therefore, we genotyped three additional southern European cohorts comprising a total of 2028 cases and 4273 controls. The meta-analysis results show that only one of the association signals (rs961253) is effectively replicated in the southern European populations, despite adequate power to detect all four. The other three SNPs (rs4444235, rs1957636 and rs4813802) presented discordant results in MAFs and linkage disequilibrium patterns between northern and southern European cohorts. We hypothesize that this lack of replication could be the result of differential tagging of the functional variant in both sets of populations. Were this true, it would have complex consequences in both our ability to understand the nature of the real causative variants, as well as for further study designs
Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats
Contains fulltext :
87589.pdf (publisher's version ) (Closed access)BACKGROUND: microsatellite instability (MSI) is commonly screened using a panel of two mononucleotide and three dinucleotide repeats as recommended by a consensus meeting on MSI tumours held at the National Cancer Institute (Bethesda, MD, USA). According to these recommendations, tumours are classified as MSI-H when at least two of the five microsatellite markers show instability, MSI-L when only one marker shows instability and MSS when none of the markers show instability. Almost all MSI-H tumours are characterised by alterations in one of the four major proteins of the mismatch repair (MMR) system (MLH1, MSH2, MSH6 or PMS2) that renders them MMR deficient, whereas MSI-L and MSS tumours are generally MMR proficient. However, tumours from patients with a pathogenic germline mutation in MSH6 can sometimes present an MSI-L phenotype with the NCI panel. The MSH6 protein is not involved in the repair of mismatches of two nucleotides in length and consequently the three dinucleotide repeats of the NCI panel often show stability in MSH6-deficient tumours. METHODS: a pentaplex panel comprising five mononucleotide repeats has been recommended as an alternative to the NCI panel to determine tumour MSI status. Several studies have confirmed the sensitivity, specificity and ease of use of the pentaplex panel; however, its sensitivity for the detection of MSH6-deficient tumours is so far unknown. Here, we used the pentaplex panel to evaluate MSI status in 29 tumours known to harbour an MSH6 defect. RESULTS: MSI-H status was confirmed in 15 out of 15 (100%) cases where matching normal DNA was available and in 28 out of 29 (97%) cases where matching DNA was not available or was not analysed. CONCLUSION: these results show that the pentaplex assay efficiently discriminates the MSI status of tumours with an MSH6 defect
Curing Efficiency of Novolac-Type PhenolâFormaldehyde Resins from Viscoelastic Properties
The curing performance of a homogeneous set of different grades of novolac-type phenolâformaldehyde (PF) resins having different structures is analyzed. The PF resins have a statistical ortho/para substitution at aromatic rings and contain from 5 to 15 wt % hexamethylenetetramine (HMTA) as a hardener. Moreover, the different analyzed grades are PF resins differently modified by addition of boron/phosphorous compounds, or an acrylic rubber, or silicone and xylene/phenol copolymers, or introduction of aralkyl modifications. The curing behavior is compared with that of an unmodified PF resin in which the cross-linking agent (HMTA) is added into the molten polymer to guarantee a good dispersion according to the hexamine adduct phenolic (HAP) technology. The effect of the different modifications is probed by rheological measurements during curing under isothermal conditions. Under similar curing conditions, the modified resins show different curing performances and lower stiffness with respect to the unmodified Ph resin obtained by HAP technology. A method to quantify the curing performance is introduced and suggested based on two relevant parameters derived from rheological measurements, the âcuring ratioâ that indicates the efficiency to generate the thermal-induced three-dimensional network and a âmaximum curing rateâ that is related to the cross-linking reaction rate. The results allow classifying the resins as belonging to different classes, depending on the combination of the curing ratio and curing rate
Enrichment of inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative trait loci
BACKGROUND: Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with diseases of the colon including inflammatory bowel diseases (IBD) and colorectal cancer (CRC). However, the functional role of many of these SNPs is largely unknown and tissue-specific resources are lacking. Expression quantitative trait loci (eQTL) mapping identifies target genes of disease-associated SNPs. This study provides a comprehensive eQTL map of distal colonic samples obtained from 40 healthy African Americans and demonstrates their relevance for GWAS of colonic diseases. RESULTS: 8.4 million imputed SNPs were tested for their associations with 16,252 expression probes representing 12,363 unique genes. 1,941 significant cis-eQTL, corresponding to 122 independent signals, were identified at a false discovery rate (FDR) of 0.01. Overall, among colon cis-eQTL, there was significant enrichment for GWAS variants for IBD (Crohn's disease [CD] and ulcerative colitis [UC]) and CRC as well as type 2 diabetes and body mass index. ERAP2, ADCY3, INPP5E, UBA7, SFMBT1, NXPE1 and REXO2 were identified as target genes for IBD-associated variants. The CRC-associated eQTL rs3802842 was associated with the expression of C11orf93 (COLCA2). Enrichment of colon eQTL near transcription start sites and for active histone marks was demonstrated, and eQTL with high population differentiation were identified. CONCLUSIONS: Through the comprehensive study of eQTL in the human colon, this study identified novel target genes for IBD- and CRC-associated genetic variants. Moreover, bioinformatic characterization of colon eQTL provides a tissue-specific tool to improve understanding of biological differences in diseases between different ethnic groups.This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at [email protected]
S1271 Plantago Ovata Husk Regulates Cell Cycle Progression and Wnt Signaling Pathway, Crucial Elements Implicated in Colorectal Carcinogenesis
S1272 Differential Regulation of Apoptosis Induction By Plantago Ovata Husk in Colorectal Cancer Cells. Induction of the TNF-Alpha Apoptosis Cascade in Metastatic Cells
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
AIM: Some retrospective studies have shown a lack of benefit of 5âfluorouracil (5âFU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5âFU adjuvant chemotherapy. A second objective was to determine if MMR status influences short term survival. METHODS: We included 754 patients with a median follow up of 728.5â
days (range 1â1097). A total of 260 patients with stage II or III tumours received 5âFU adjuvant chemotherapy, according to standard clinical criteria and irrespective of their MMR status. A tumour was considered MMR deficient when either BATâ26 showed instability or there was loss of MLH1 or MSH2 protein expression. RESULTS: At the end of the follow up period, 206 patients died and 120 presented with tumour recurrence. Sixty six (8.8%) patients had MMR deficient tumours. There were no significant differences in overall survival (MMR competent 72.1%; MMR deficient 78.8%; pâ=â0.3) or disease free survival (MMR competent 61.3%; MMR deficient 72.3%; pâ=â0.08). In patients with stage II and III tumours, benefit from 5âFU adjuvant chemotherapy was restricted to patients with MMR competent tumours (overall survival: chemotherapy 87.1%; nonâchemotherapy 73.5%; log rank, pâ=â0.00001). Patients with MMR deficient tumours did not benefit from adjuvant chemotherapy (overall survival: chemotherapy 89.5%; nonâchemotherapy 82.4%; log rank, pâ=â0.4). CONCLUSIONS: Benefit from 5âFU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer. 5âFU adjuvant chemotherapy improves survival in patients with MMR competent tumours but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours